DNA adduct profiles predict in vitro cell viability after treatment with the experimental anticancer prodrug PR104A

Alessia Stornetta, Peter W. Villalta, Frederike Gossner, William R. Wilson, Silvia Balbo, Shana J. Sturla

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

PR104A is an experimental DNA-alkylating hypoxiaactivated prodrug that can also be activated in an oxygen-independent manner by the two-electron aldo-keto reductase 1C3. Nitroreduction leads to the formation of cytotoxic hydroxylamine (PR104H) and amine (PR104M) metabolites, which induce DNA mono and cross-linked adducts in cells. PR104A-derived DNA adducts can be utilized as drugspecific biomarkers of efficacy and as a mechanistic tool to elucidate the cellular and molecular effects of PR104A. Toward this goal, a mass spectrometric bioanalysis approach based on a stable isotope-labeled adduct mixture (SILAM) and selected reaction monitoring (SRM) data acquisition for relative quantitation of PR104A-derived DNA adducts in cells was developed. Use of this SILAM-based approach supported simultaneous relative quantitation of 33 PR104A-derived DNA adducts in the same sample, which allowed testing of the hypothesis that the enhanced cytotoxicity, observed by preconditioning cells with the transcription-activating isothiocyanate sulforaphane, is induced by an increased level of DNA adducts induced by PR104H and PR104M, but not PR104A. By applying the new SILAM-SRM approach, we found a 2.4-fold increase in the level of DNA adducts induced by PR104H and PR104M in HT-29 cells preconditioned with sulforaphane and a corresponding 2.6-fold increase in cytotoxicity. These results suggest that DNA adduct levels correlate with drug potency and underly the possibility of monitoring PR104A-derived DNA adducts as biomarkers of efficacy.

Original languageEnglish (US)
Pages (from-to)830-839
Number of pages10
JournalChemical research in toxicology
Volume30
Issue number3
DOIs
StatePublished - 2017

Fingerprint Dive into the research topics of 'DNA adduct profiles predict in vitro cell viability after treatment with the experimental anticancer prodrug PR104A'. Together they form a unique fingerprint.

  • Cite this